Larissa A Meyer1, Weiguo He2, Charlotte C Sun3, Hui Zhao2, Alexi A Wright4, Rudy S Suidan3, Joseph Dottino3, J Alejandro Rauh-Hain3, Karen H Lu3, Sharon H Giordano2. 1. The University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, Houston, TX, United States of America. Electronic address: lmeyer@mdanderson.org. 2. The University of Texas MD Anderson Cancer Center, Department of Health Services Research, Houston, TX, United States of America. 3. The University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, Houston, TX, United States of America. 4. Dana-Farber/Brigham and Womens Cancer Center, Boston, MA, United States of America.
Abstract
BACKGROUND: Neoadjuvant chemotherapy (NACT) may reduce perioperative morbidity in women undergoing primary treatment for ovarian cancer. We evaluated patterns of use and outcomes in a population-based cohort of elderly women with ovarian cancer (OC). METHODS: A cohort of patients ≥66 years old diagnosed between 2000 and 2013 with stage III-IV epithelial OC who received surgery and platinum/taxane chemotherapy for primary treatment was identified from the SEER-Medicare database. Propensity-score matching methods were used to examine differences in outcomes. Kaplan-Meier analysis was performed to compare overall survival (OS) in the matched cohort. RESULTS: From 2000 to 2013, 22.5% of older women received NACT. The use of NACT increased over time from 16% in 2000 to 35.4% in 2013 (p < .0001). Among women who received PCS, the rate of ostomy creation was higher compared with NACT (23.3% vs. 10.8%, p < .0001). Infectious and other surgical complications were higher among those who had PCS, regardless of stage. Median OS of women III ovarian cancer who underwent PCS was longer compared with NACT (38.8 vs. 28 months, p ≤ .0001). There were no survival differences between NACT and PCS in women with stage IV disease (29.4 vs. 29.8 months, p = .61) or for women aged >80. CONCLUSION: Careful consideration should be given to older patients prior to undergoing PCS. Survival outcomes were similar for patients with stage IV disease, although NACT was associated with decreased perioperative morbidity compared with PCS. Among women with stage III disease, PCS was associated with improved overall survival, but higher rates of perioperative morbidity and acute care.
BACKGROUND: Neoadjuvant chemotherapy (NACT) may reduce perioperative morbidity in women undergoing primary treatment for ovarian cancer. We evaluated patterns of use and outcomes in a population-based cohort of elderly women with ovarian cancer (OC). METHODS: A cohort of patients ≥66 years old diagnosed between 2000 and 2013 with stage III-IV epithelial OC who received surgery and platinum/taxane chemotherapy for primary treatment was identified from the SEER-Medicare database. Propensity-score matching methods were used to examine differences in outcomes. Kaplan-Meier analysis was performed to compare overall survival (OS) in the matched cohort. RESULTS: From 2000 to 2013, 22.5% of older women received NACT. The use of NACT increased over time from 16% in 2000 to 35.4% in 2013 (p < .0001). Among women who received PCS, the rate of ostomy creation was higher compared with NACT (23.3% vs. 10.8%, p < .0001). Infectious and other surgical complications were higher among those who had PCS, regardless of stage. Median OS of women III ovarian cancer who underwent PCS was longer compared with NACT (38.8 vs. 28 months, p ≤ .0001). There were no survival differences between NACT and PCS in women with stage IV disease (29.4 vs. 29.8 months, p = .61) or for women aged >80. CONCLUSION: Careful consideration should be given to older patients prior to undergoing PCS. Survival outcomes were similar for patients with stage IV disease, although NACT was associated with decreased perioperative morbidity compared with PCS. Among women with stage III disease, PCS was associated with improved overall survival, but higher rates of perioperative morbidity and acute care.
Authors: Raj Naik; Nick Spirtos; Christophe Pomel; Rob Bristow; Dennis Chi; Ignace Vergote; Jenny Donovan Journal: Int J Gynecol Cancer Date: 2013-05 Impact factor: 3.437
Authors: Melissa M Thrall; Heidi J Gray; Rebecca Gaston Symons; Noel S Weiss; David R Flum; Barbara A Goff Journal: Gynecol Oncol Date: 2011-09-26 Impact factor: 5.482
Authors: Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245
Authors: Dennis S Chi; Fernanda Musa; Fanny Dao; Oliver Zivanovic; Yukio Sonoda; Mario M Leitao; Douglas A Levine; Ginger J Gardner; Nadeem R Abu-Rustum; Richard R Barakat Journal: Gynecol Oncol Date: 2011-09-13 Impact factor: 5.482
Authors: A Fagotti; G Vizzielli; F Fanfani; B Costantini; G Ferrandina; V Gallotta; S Gueli Alletti; L Tortorella; G Scambia Journal: Gynecol Oncol Date: 2013-08-09 Impact factor: 5.482
Authors: J Alejandro Rauh-Hain; Alexander Melamed; Alexi Wright; Allison Gockley; Joel T Clemmer; John O Schorge; Marcela G Del Carmen; Nancy L Keating Journal: JAMA Oncol Date: 2017-01-01 Impact factor: 31.777
Authors: Olga T Filippova; Dennis S Chi; Kara Long Roche; Yukio Sonoda; Oliver Zivanovic; Ginger J Gardner; William P Tew; Roisin O'Cearbhaill; Saman Sarraf; Sung Wu Sun; Koshy Alexander; Beatriz Korc-Grodzicki; Armin Shahrokni Journal: Gynecol Oncol Date: 2019-05-08 Impact factor: 5.482
Authors: Joseph A Dottino; Weiguo He; Charlotte C Sun; Hui Zhao; Shuangshuang Fu; Jose Alejandro Rauh-Hain; Rudy S Suidan; Karen H Lu; Sharon H Giordano; Larissa A Meyer Journal: Int J Gynecol Cancer Date: 2020-07-02 Impact factor: 3.437
Authors: Ross F Harrison; Scott B Cantor; Charlotte C Sun; Mariana Villanueva; Shannon N Westin; Nicole D Fleming; Iakovos Toumazis; Anil K Sood; Karen H Lu; Larissa A Meyer Journal: Gynecol Oncol Date: 2021-01-31 Impact factor: 5.482
Authors: Olga T Filippova; Amy L Tin; Joanne Alonso; Andrew J Vickers; William P Tew; Ginger J Gardner; Yukio Sonoda; Kara Long Roche; Oliver Zivanovic; Dennis S Chi; Armin Shahrokni Journal: Gynecol Oncol Date: 2021-03-25 Impact factor: 5.304
Authors: Christopher G Smith; Daniel L Davenport; Justin Gorski; Anthony McDowell; Brian T Burgess; Tricia I Fredericks; Lauren A Baldwin; Rachel W Miller; Christopher P DeSimone; Charles S Dietrich; Holly H Gallion; Edward J Pavlik; John R van Nagell; Frederick R Ueland Journal: Healthcare (Basel) Date: 2019-07-03
Authors: Ying L Liu; Olga T Filippova; Qin Zhou; Alexia Iasonos; Dennis S Chi; Oliver Zivanovic; Yukio Sonoda; Ginger J Gardner; Vance A Broach; Roisin E O'Cearbhaill; Jason A Konner; Carol Aghajanian; Kara Long Roche; William P Tew Journal: J Gynecol Oncol Date: 2020-01 Impact factor: 4.401